A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
NCT ID: NCT00001042
Last Updated: 2021-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
112 participants
INTERVENTIONAL
1996-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PER AMENDMENT 3/6/96: Purpose of the extension study - To determine the ability of immunization with rgp 120/SF-2 to induce an HIV-1 envelope-specific delayed-type hypersensitivity (DTH) response in volunteers who receive rsgp 120/MN skin testing.
One approach to improve the immunogenicity of an HIV-1 subunit protein vaccine is to combine the immunogen with an adjuvant. Adjuvants may augment vaccine immunogenicity by several mechanisms, and as a result induce a more favorable antibody response with high titers, which appear earlier in the course of immunization and persist over time.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Volunteers are randomized to receive 50 mcg rgp120/HIV-1SF2 in combination with one of seven different adjuvants: aluminum hydroxide (alum), monophosphoryl lipid A, liposome-encapsulated monophosphoryl lipid A, MF59, MTP-PE/MF59, Syntex adjuvant formulation (SAF/2), and SAF/2 plus threonyl muramyl dipeptide (threonyl MDP). An additional placebo control arm of volunteers receive alum only. Doses are administered at 0, 2, and 6 months. Volunteers are followed for 1 year after the last immunization. Per 8/5/94 amendment, eligible volunteers except those who received monophosphoryl lipid A for the first three immunizations may receive a fourth dose at month 15.
PER AMENDMENT 3/6/96: Extension Study- Protocol 015 has been modified to add a special DTH study. At the end of the study, on day 784, intradermal injections of MN rsgp 120 will be administered to consenting volunteers who have received 4 immunizations as part of protocol 015. Follow up will be extended to 56 days after administration of the intradermal injections.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aluminum hydroxide
Lipid A, Monophosphoryl
Lipid A, Liposome-encapsulated monophosphoryl
Syntex adjuvant formulation
MF59
Threonyl Muramyl Dipeptide
rgp120/HIV-1 SF-2
MTP-PE/MF59
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HIV negativity by ELISA.
* Normal history and physical exam.
* CD4 count \>= 400 cells/mm3.
* Lower risk sexual behavior.
* Normal urine dipstick with esterase and nitrite.
PER AMENDMENT 3/6/96:
* Extension study -
* Consenting Protocol 015 volunteers who have received four immunizations.
Exclusion Criteria
Subjects with the following symptoms or conditions are excluded:
* Hepatitis B surface antigen.
* Active syphilis. NOTE:Subjects for whom serology is documented to be a false positive or due to a remote (\> 6 months) treated infection are eligible.
* Active tuberculosis. NOTE:Subjects with a positive PPD and normal chest x-ray showing no evidence of TB and not requiring isoniazid therapy are eligible.
* Medical or psychiatric condition or occupational responsibilities that would preclude compliance.
Subjects with the following prior conditions are excluded:
* History of immunodeficiency, chronic illness, or autoimmune disease.
* History of anaphylaxis or other serious adverse reactions to vaccines.
PER AMENDMENT 3/6/96: Extension study -
* History of eczema or allergic-type reactions to vaccine in Protocol 015.
Prior Medication:
Excluded:
* Live attenuated vaccines within 60 days prior to study entry. (NOTE: Medically indicated subunit or killed vaccines, such as influenza or pneumococcal, are allowed but should be given at least 2 weeks prior to HIV immunizations.)
* Experimental agents within 30 days prior to study entry.
* Prior HIV vaccines.
PER AMENDMENT 3/6/96: Extension study -
* Use of systemic steroids in the past month.
Prior Treatment:
Excluded:
* Blood products or immunoglobulin within 6 months prior to study entry. Higher risk behavior for HIV infection (as determined by screening questionnaire), including history of injection drug use within the last 12 months and higher or intermediate risk sexual behavior.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
McElrath J
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Louis Univ. School of Medicine AVEG
St Louis, Missouri, United States
Univ. of Rochester AVEG
Rochester, New York, United States
UW - Seattle AVEG
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zolla-Pazner S, Alving C, Belshe R, Berman P, Burda S, Chigurupati P, Clements ML, Duliege AM, Excler JL, Hioe C, Kahn J, McElrath MJ, Sharpe S, Sinangil F, Steimer K, Walker MC, Wassef N, Xu S. Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines. J Infect Dis. 1997 Apr;175(4):764-74. doi: 10.1086/513969.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10563
Identifier Type: REGISTRY
Identifier Source: secondary_id
AVEG 015
Identifier Type: -
Identifier Source: org_study_id